0000891293-17-000106.txt : 20171003 0000891293-17-000106.hdr.sgml : 20171003 20171003161216 ACCESSION NUMBER: 0000891293-17-000106 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170929 FILED AS OF DATE: 20171003 DATE AS OF CHANGE: 20171003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KIRSKE DAVID CENTRAL INDEX KEY: 0001276750 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 171117960 MAIL ADDRESS: STREET 1: C/O CTI BIOPHARMA CORP. STREET 2: 3101 WESTERN AVE., SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2017-09-29 0 0000891293 CTI BIOPHARMA CORP ctic 0001276750 KIRSKE DAVID 3101 WESTERN AVE., SUITE 600 SEATTLE WA 98121 0 1 0 0 EVP, Chief Financial Officer Non-Qualified Stock Option (right to buy) 3.19 2017-09-29 4 A 0 315000 0 A 2027-09-29 Common Stock 315000 315000 D The stock options will vest in six equal semi-annual installments over a three-year period beginning September 29, 2017 subject to continued employment by CTIC through the applicable vesting dates. Bruce J. Seeley, Attorney-in-fact For: David Kirske 2017-10-03